Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. Promore Pharma has two programs in late-stage clinical development: ensereptide (PXL01), aimed for prevention of post-surgical adhesions and dermal scarring and ropocamptide (LL-37) for chronic leg ulcers treatment. Promore Pharma listed on NASDAQ First North in 2017